Global Statistics

All countries
178,635,352
Confirmed
Updated on June 19, 2021 4:39 am
All countries
161,435,957
Recovered
Updated on June 19, 2021 4:39 am
All countries
3,867,842
Deaths
Updated on June 19, 2021 4:39 am
Saturday, June 19, 2021

Global Statistics

All countries
178,635,352
Confirmed
Updated on June 19, 2021 4:39 am
All countries
161,435,957
Recovered
Updated on June 19, 2021 4:39 am
All countries
3,867,842
Deaths
Updated on June 19, 2021 4:39 am
Molderizer and Safe Shield

Eli Lilly signs deals to boost supply of COVID-19 treatment in India

Dutch take ‘big step’ towards ending coronavirus curbs

The Netherlands has announced further easing of a raft of measures to combat coronavirus, including an end to mask-wearing in most places. Prime Minister...

[Bookmark] Evidence Stacks Up: Signals COVID-19 Emerged from the Wuhan Lab

~~ Bookmark is a JAPAN Forward feature that gives you long reads for the weekend. Each edition introduces one overarching thought that branches...

Chandrababu Briefs Precautions To Be Taken By Individuals || Coronavirus Prevention || NTV

Chandrababu Briefs Precautions To Be Taken By Individuals || Coronavirus Prevention #Chandrababu #APCoronavirus Watch Ntv Live Here: ... source

New cases of highly infectious COVID strain discovered in U.S.

Florida is the latest state to report a case of the more contagious variant of COVID-19. California and Colorado have also reported cases. Manuel...


Eli Lilly and Co (LLY.N) said on Monday it had signed licensing agreements with three Indian generic drugmakers to expand the availability of its arthritis drug baricitinib in the country for treating COVID-19 patients.

The agreements will bolster India’s arsenal of drugs to battle its catastrophic second wave of the pandemic, which has led to an acute shortage of coronavirus medicines including remdesivir and tocilizumab.

The three Indian drugmakers – Cipla Ltd (CIPL.NS), Lupin Ltd (LUPN.NS) and Sun Pharma (SUN.NS) – will collaborate with U.S.-based Lilly to help make and sell baricitinib in India.

Baricitinib has been given restricted emergency use approval by India’s drug regulator for use in combination with remdesivir for the treatment of hospitalised COVID-19 adult patients requiring supplemental oxygen, Eli Lilly said in an emailed statement.

The U.S. Food and Drug Administration initially gave Lilly an emergency use approval in November for baricitinib in combination with remdesivir to treat COVID-19 patients.

“More licenses to additional Indian generic manufacturers are expected to be announced soon,” said Luca Visini, managing director at Lilly India, without elaborating further.

Last week, Lilly said it would donate 400,000 tablets of baricitinib, to be used with remdesivir, to the Indian government. read more

These agreements would expand the portfolio of COVID-19 drugs offered by the country’s drugmakers. All three companies offer antiviral drug favipiravir, used to treat patients with moderate to mild COVID-19.

Cipla, which also offers remdesivir and tocilizumab, said last week it would be the local distribution partner for a COVID-19 antibody drug cocktail developed by Roche (ROG.S) and Regeneron (REGN.O), after the therapy got domestic emergency use approval. read more

Separately, smaller Indian drugmaker Natco Pharma (NATP.NS)said earlier this month it would request a compulsory license based on emergency approval for its own generic version of baricitinib.

India reported 366,161 new infections and 3,754 deaths on Monday, dipping from recent peaks, while calls grew for a nationwide lockdown. read more

Our Standards: The Thomson Reuters Trust Principles.



Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Popular

Dutch take ‘big step’ towards ending coronavirus curbs

The Netherlands has announced further easing of a raft of measures to combat coronavirus, including an end to mask-wearing in most places. Prime Minister...

[Bookmark] Evidence Stacks Up: Signals COVID-19 Emerged from the Wuhan Lab

~~ Bookmark is a JAPAN Forward feature that gives you long reads for the weekend. Each edition introduces one overarching thought that branches...

Related Articles

Dutch take ‘big step’ towards ending coronavirus curbs

The Netherlands has announced further easing of a raft of measures to combat coronavirus, including an end to mask-wearing in most places. Prime Minister...

[Bookmark] Evidence Stacks Up: Signals COVID-19 Emerged from the Wuhan Lab

~~ Bookmark is a JAPAN Forward feature that gives you long reads for the weekend. Each edition introduces one overarching thought that branches...